AUTHOR: IBNET Final clinical trials for a vaccine developed by AstraZeneca, a UK-Swedish drug firm, and Oxford University, have been halted after a subject in the UK became sick. In April, Oxford partnered the biopharmaceutical giant for the development of a COVID-19 vaccine, projecting it could begin supply in September if clinical trials were successful. According to the BBC , AstraZeneca, on Tuesday, said it has now paused the late-stage trials of the experimental COVID-19 vaccine after a study participant developed an unexplained illness. After successful phase one and two trials, the developers, on September 3, initiated the third trial , which is said to have involved about 30,000 participants in the US, the UK, Brazil and South Africa. AstraZeneca described the pause as a “routine”, and it said the development is as a result of the trial being closely watched around the globe. “We have no idea whether this is a big deal or not Science is...